Pharma Forecast - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharma Forecast
A recent reader poll focused on predictions for the industry's future.

Pharmaceutical Technology
Volume 33, Issue 2, pp. 14

Alexis Pellek
For the second year in a row, PharmTech asked readers in an online poll what area of the pharmaceutical industry they think will experience the most change in the upcoming year. Respondents said that for 2009, regulation policy and enforcement would change the most (25%), followed by manufacturing equipment and processes (23%), and outsourcing and consulting services (17%).

These results differ slightly from what PharmTech readers thought about 2008, when outsourcing (33%) was the number 1 pick, followed by regulation (23%) and information technology (15%). As it turned out, outsourcing was a big topic in 2008. Most notably, there was Baxter's January recall of heparin products and the later discovery that the contaminated active ingredient came from a supplier in China. Later in the year, news arose of the negative impact that last year's economic meltdown had on the third-quarter reports of contract research and manufacturing organizations.

For 2009, readers seem to expect the most news and change in the area of regulation. As the Obama administration works with new staff at FDA, we might see the agency take on topics such as increased oversight of direct-to-consumer advertising, more implementation of quality systems, the development of a regulatory pathway for follow-on biologics, and an emphasis on foreign inspections.

To cast your vote in our biweekly polls and to see the results of past questions, visit our poll archive at

Alexis Pellek is an assistant editor of Pharmaceutical Technology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here